National Survey of Precision Medicine in Cancer Treatment

The National Survey of Precision Medicine in Cancer Treatment was the first nationally representative survey of oncologists about the current practice of precision medicine in cancer treatment.

Genetic, genomic, and biomarker tests are transforming cancer care and treatment. However, the development and diffusion of gene expression profiling and next generation sequencing tests have out-paced the generation of data on their clinical utility and the development of clinical guidelines. Few studies have evaluated physicians’ experiences using genomic tests and how their experiences may differ across practice settings.

The National Survey of Precision Medicine in Cancer Treatment was fielded to better understand how oncologists use genomic testing to inform treatment recommendations; their confidence in using genomic test results to guide care; as well as key barriers, drivers, and other factors that influence their use of genomic testing in clinical practice. A nationally representative sample of 1,281 medical oncologists, hematologists-oncologists, and hematologists practicing in the continental United States participated in the survey. Data were collected from February through May of 2017.

The National Survey of Precision Medicine in Cancer Treatment was sponsored by the National Cancer Institute, with support from the American Cancer Society and National Human Genome Research Institute.

Survey Instrument

The National Survey of Precision Medicine in Cancer Treatment is publicly available.

Download the survey:

Publications

Please refer to the following publications for additional information about the National Survey of Precision Medicine in Cancer Treatment.

Outcomes

Freedman AN, Klabunde CN, Wiant K, Enewold L, Gray SW, Filipski KK, Keating NL, Leonard DGB, Lively T, McNeel TS, Minasian L, Potosky AL, Rivera DR, Schilsky RL, Schrag D, Simonds NI, Sineshaw HM, Struewing JP, Willis G, de Moor JS. Use of Next-Generation Sequencing Tests to Guide Cancer Treatment: Results From a Nationally Representative Survey of Oncologists in the United States. JCO Precision Oncology 2018 :2, 1-13 [Full TextExternal Web Site Policy]

Methods

Wiant K, Geisen E, Creel D, Willis G, Freedman A, de Moor J, Klabunde C. Risks and rewards of using prepaid vs. postpaid incentive checks on a survey of physicians. BMC Med Res Methodol. 2018 Oct 11;18(1):104. doi: 10.1186/s12874-018-0565-z. [AbstractExternal Web Site Policy]

Last Updated: 08 Aug, 2019